Dopaminergic treatment of nonfunctioning pituitary adenomas

Nature Clinical Practice Endocrinology and Metabolism

Volumn 3, Issue 8, 2007, Pages 554-555

  Greenman, Yona ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT;

CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURGERY; DIAGNOSTIC IMAGING; DOPAMINERGIC ACTIVITY; DRUG POTENCY; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; MORTALITY; NONFUNCTIONING PITUITARY ADENOMA; PRIORITY JOURNAL; RADIATION SICKNESS; RECEPTOR UPREGULATION; SHORT SURVEY; TRANSSPHENOIDAL SURGERY;

ADENOMA; BROMOCRIPTINE; DOPAMINE AGENTS; DOPAMINE AGONISTS; ERGOLINES; HUMANS; PITUITARY NEOPLASMS; PROLACTIN;

EID: 34447628685     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet0558     Document Type: Short Survey

References (10)

1. Gittoes NJ (2003) Radiotherapy for nonfunctioning pituitary tumors - when and under what circumstances? Pituitary 6: 103-108
2. Tomlinson JW et al. (2001) Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 357: 425-431
3. Feigl GC et al. (2002) Effects of gamma knife radiosurgery of pituitary adenomas on pituitary function. J Neurosurg 97 (Suppl 5): 415-421
4. Turner HE et al (1999) Audit of selected patients with nonfunctioning pituitary adenomas treated without irradiation - a follow-up study. Clin Endocrinol (Oxf) 51: 281-284
5. Park P (2004) The role of radiation therapy after surgical resection of nonfunctional pituitary macroadenomas. Neurosurgery 55: 100-106
6. Greenman Y et al. (2003) Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumor quiescence and regrowth. Clin Endocrinol (Oxf) 58: 763-769
7. Bevan JS et al. (1992) Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 13: 220-240
8. Greenman Y et al. (2005) Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumor remnant growth. Clin Endocrinol (Oxf) 63: 39-44
9. Pivonello R et al. (2004) Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. J Clin Endocrinol Metab 89: 1674-1683
10. Zanettini R et al. (2007) Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356: 39-46